









Markets
/
Stocks
/
nasdaq-armp
/

Armata Pharmaceuticals Inc

ARMP

5.740USD

+0.080+1.41%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

207.75MMarket Cap

LossP/E TTM



Armata Pharmaceuticals Inc

5.740

+0.080+1.41%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Armata Pharmaceuticals Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Armata Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

112 / 407

Overall Ranking

228 / 4615

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

9.000

Target Price

+59.01%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Armata Pharmaceuticals Inc Highlights

StrengthsRisks

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.

Growing

The company is in a growing phase, with the latest annual income totaling USD 5.17M.

Undervalued

The company’s latest PE is -8.08, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 732.82K shares, decreasing 7.44% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 7.75, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

7.75

Change



Financials

3.60

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.47

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.69

Key Metrics

Free cash flow

No Data

Armata Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 6.45, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -8.08, which is -100.00% below the recent high of 0.00 and -2570.48% above the recent low of -215.85.

Score

Industry at a Glance

Previous score

6.45

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 112/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 8.00, which is equal to the Biotechnology & Medical Research industry's average of 8.00. The average price target for Armata Pharmaceuticals Inc is 9.00, with a high of 9.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

9.000

Target Price

+59.01%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Armata Pharmaceuticals Inc

ARMP

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 7.05, which is higher than the Biotechnology & Medical Research industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 13.67 and the support level at 0.47, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.05

Change

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.002

Buy

RSI(14)

63.902

Neutral

STOCH(KDJ)(9,3,3)

46.693

Buy

ATR(14)

1.569

High Vlolatility

CCI(14)

23.196

Neutral

Williams %R

81.917

Oversold

TRIX(12,20)

2.330

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

5.196

Buy

MA10

5.272

Buy

MA20

4.693

Buy

MA50

3.656

Buy

MA100

2.985

Buy

MA200

2.372

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-06

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Innoviva Inc

25.08M

The Vanguard Group, Inc.

Star Investors

260.07K

Geode Capital Management, L.L.C.

104.55K

-1.22%

Edgewood Management LLC

100.00K

Pastagia (Mina M.D.)

61.08K

Bridgeway Capital Management, LLC

44.68K

State Street Investment Management (US)

40.30K

Renaissance Technologies LLC

Star Investors

38.90K

+0.78%

Seacrest Wealth Management, LLC

34.95K

GSB Wealth Management, LLC

30.00K

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 3.09, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.27. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.